Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

Luca Gattinoni[1,*], **Xiao-Song Zhong**[1,*], **Douglas C Palmer**[1], **Yun Ji**[1], **Christian S Hinrichs**[1], **Zhiya Yu**[1], **Claudia Wrzesinski**[1], **Andrea Boni**[1], **Lydie Cassard**[1], **Lindsay Church**[1], **Chrystal M Paulos**[1], **Pawel Muranski**[1], and **Nicholas P Restifo**[1]

[1] Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

Abstract

Self-renewing cell populations such as hematopoietic stem cells and memory B and T lymphocytes might be regulated by shared signaling pathways[1]. Wnt/β-catenin is an evolutionarily conserved pathway that promotes hematopoietic stem cell self-renewal and multipotency by limiting stem cell proliferation and differentiation[2,3], but its role in the generation and maintenance of memory T cells is unknown. We found that the induction of Wnt/β-catenin signaling using inhibitors of glycogen-sythase-kinase-3β or the Wnt protein family member, Wnt3a, arrested CD8$^+$ T cell development into effector cells. By blocking T-cell differentiation, Wnt signaling enabled the generation of CD44^{low}, CD62L^{high}, Sca-1^{high}, CD122^{high}, Bcl-2^{high} self-renewing, multipotent CD8$^+$ memory stem cells with proliferative and anti-tumor capacities exceeding those of central and effector memory T cell subsets. These findings reveal a key role for Wnt signaling in the maintenance of stemness in mature memory CD8$^+$ T cells and have important implications for the design of novel vaccination strategies and adoptive immunotherapies.

T cell factor (Tcf) 1 and lymphoid enhancer-binding factor (Lef) 1 are downstream transcription factors of the Wnt/β-catenin signaling pathway. Tcf1 and Lef1 are required for normal thymic T cell development, but less is known about Wnt function in mature T cells[2,4]. Although experiments using multimerized TCF/LEF binding site reporter system have revealed that Wnt signaling is active in mature CD8$^+$ T cells, the impact of this pathway to this cell population has yet to be fully elucidated[5]. At least three lines of evidence indicate that Wnt signaling might regulate the maturation of post-thymic T lymphocytes: *i.*) CD8$^+$ T cells from *Tcf7*$^{-/-}$ mice, which are missing the gene that encodes for TCF1, display a more differentiated phenotype (CD44^{high} and CD62L^{low}) than WT T cells[6]; *ii.*) expression of *Lef1* and *Tcf7*, decreases with progressive differentiation of CD8$^+$ T cells from naive (T$_N$) → central memory (T$_{CM}$) → effector memory (T$_{EM}$) inhumans[7] and mouse (Supplementary Fig. 1); and *iii.*) high levels of *Ctnnb1* (which encodes β-catenin),

Address correspondence to Luca Gattinoni or Nicholas P. Restifo, National Cancer Institute, National Institutes of Health, Clinical Research Center, Room 3-5762, 10 Center Drive, Bethesda, MD 20892-1502. E-mail: (LG): gattinol@mail.nih.gov, (NPR): restifo@nih.gov.
*These authors contributed equally to the present work.

Lef1, *Tcf7* have been detected in T cells with increased potential to form memory *in vivo*[8,9]. Thus, triggering the activities of the Wnt signaling transcription factors TCF1 and LEF1 could promote stem-like self-renewal capacity in mature T cells.

To test the impact of Wnt/β-catenin signaling on mature CD8[+] T cells, we primed T_N in the presence of the 4,6-disubstituted pyrrolopyrimidine TWS119, a potent inhibitor of the serine/threonine kinase glycogen-synthase-kinase-3β (Gsk-3β)[10]. Gsk-3β blockade mimics Wnt signaling by promoting the accumulation of β-catenin, the molecule that tethers the TCF and LEF transcription factors to targeted DNA[2]. TWS119 triggered a rapid accumulation of β-catenin (mean 6.8 +/− SD 1.7-fold increase by densitometry; $p < 0.05$) (Fig. 1a), augmented nuclear protein-TCF/LEF oligonucleotide interaction (Fig. 1b) and sharply up-regulated *Tcf7*[11], *Lef1*[12] and other Wnt target genes including *Jun*[13], *Frizzled7* (*Fzd7*)[14], *Nemo-like-kinase* (*Nlk*)[15] (Fig. 1c). By contrast, T cell activation in the absence of the Gsk-3β inhibitor resulted in the down-regulation of the Wnt/β-catenin pathway at these steps of the signaling cascade (Fig. 1a–c). Thus, TWS119 activated the Wnt/β-catenin pathway in naive T cells and reversed the physiological down-regulation of *Tcf7* and *Lef1* induced by T cell activation[7].

We sought to assess the effect of Wnt signaling on CD8[+] T cell differentiation and proliferation. We stimulated CFSE-labeled CD8[+] T cells from pmel-1 TCR transgenic mice[16] with the cognate antigen, gp100, in the presence of titrated doses of TWS119 and analyzed them for the expression of the differentiation markers CD44 and CD62L. CD44 expression is known to increase with T cell differentiation while CD62L is progressively lost[17]. TWS119 increased the frequency of T cells that retained CD62L expression in a dose-dependent manner, indicating that it inhibited CD8[+] T cell differentiation (Fig. 2a). Interestingly, 46% of CD8[+] T cells cultured in the presence of the highest concentration of Gsk-3β inhibitor failed to up-regulate CD44, maintaining a "naive" CD44[low]CD62L[high] phenotype (Fig. 2a). Low doses of TWS119 (1 μM) preserved CD62L expression without affecting T cell proliferation, while higher drug concentrations promoted a dose-dependent inhibition of cell cycling (Fig. 2b). Arrested differentiation and proliferation of CD8[+] T cells by TWS119 was not secondary to the impact of the drug on dendritic cells (DC), because we observed similar results stimulating purified CD8[+] T cells in a DC-free system (Supplementary Fig. 2a,b). Similar to TWS119, we found that the structurally unrelated Gsk-3β inhibitor, 6-bromo-substituted indirubin, BIO[18,19], inhibited T cell differentiation (Supplementary Fig. 3a) and induced the expression of the Wnt transcription factors *Tcf7* and *Lef1* (Supplementary Fig. 3b). The use of an analog, BIO-acetoxime[19], with a greater Gsk-3β kinase inhibitory specificity, retained the observed activity while the use of N-methylated analog (Methyl-BIO)[19], a kinase inactive control, had no effect (Supplementary Fig. 3a,b). These results are in contrast with those obtained using lithium chloride[20] as a Gsk-3β inhibitor, which is less active and specific than the inhibitors used in the present study[19]. Because Gsk-3β regulates several signaling pathways other than Wnt, we sought to more directly test whether the impact of the pharmacological blockade of Gsk-3β was dependent on mimicking the downstream signals of the Wnt/β-catenin pathway. We primed CD8[+] T cells in the presence of Wnt3A, a Wnt protein that has been shown to promote stem cell self-renewal and pluripotency *via* β-catenin accumulation in the cell nucleus[21]. Like

TWS119, we found that Wnt3A itself inhibited T cell differentiation and proliferation (Supplementary Fig. 4). Thus, T cell proliferation and differentiation could be restrained through the activation of the Wnt/β-catenin pathway by the naturally-occuring ligand, Wnt3A, and by the pharamcologic inhibition of Gsk-3β downstream. Neverthelss, our data did not rule out the possibility that Gsk-3β inhibitors were regulating T cell differentiation by affecting other pathways in addition to Wnt.

We sought to evaluate whether the phenotypic differences of pmel-1 CD8$^+$ T cells induced by TWS119 were associated with functional changes. It has been previously shown that differentiating CD8$^+$ T cells lose the capacity to produce IL-2 as they acquire the ability to kill target cells and release high levels of IFN-γ[17,22]. We found that TWS119 induced a dose-dependent decrease in T cell-specific killing and IFN-γ release associated with a preservation in the ability to produce IL-2 (Fig. 2c). These functional data confirmed the phenotypic findings that TWS119 was a negative regulator of T_{EFF} differentiation. We next assessed if the inhibition of T_{EFF} development was associated with the suppression of eomesodermin (Eomes), a master regulator of CD8$^+$ T-cell effector function[23]. We found that the exposure of cells to TWS119 abrogated the induced expression of *Eomes* that occurred within 8h after T cell priming, indicating that TWS119-mediated suppression of the effector program was an early event (Fig. 2d). Altogether, phenotypic, functional and molecular data indicated that induction of Wnt signaling during T cell priming resulted in an inhibition of CD8$^+$ T cell differentiation into T_{EFF} cells. Given our *in vitro* findings, we tested whether TWS119 could influence the qualities of adoptively transferred pmel-1 CD8$^+$ T cells in response to fowlpox-based gp100 immunization and prevent the induction of highly differentiated, senescent T cells, a major pitfall of current T cell-based vaccines[24]. We found that there were no differences in frequency or numbers of pmel-1 T cells in spleens six days after vaccination, but the development of T_{EFF} was inhibited (Fig. 2e). More importantly, TWS119 augmented the numbers of CD44^{high}, CD62L^{high} T_{CM} in responding CD8$^+$ T cells in the post-vaccination setting(Fig. 2e). Although the present approach does not enable the dissection of the cellular mechanism of action *in vivo*, TWS119 effectively altered CD8$^+$ T cell differentiation after immunization.

We observed a cell population that expressed low levels of CD44 and high levels of CD62Lwhen TWS119 was administered *in vitro* and *in vivo* (Fig. 2a,e) but it was unclear whether these cells remained naive after antigen encounter or had entered into a primordial memory state that retained some phenotypic traits of T_N. Using a murine model of graft-versus-host disease, Zhang *et al.* have described population of CD44^{low} CD62L^{high} memory CD8$^+$ T cells that expressed high levels of stem cell antigen-1 (Sca-1), B-cell lymphoma protein 2 (Bcl-2), and common IL-2/IL-15 receptor β chain (CD122)[25]. Because these cells displayed robust self-renewal and the multipotent capacity to derive T_{CM}, T_{EM}, and T_{EFF} they were designated "T memory stem cells" (T_{SCM})[25]. We sought to explore whether the CD44^{low} CD62L^{high} pmel-1 T cells generated *in vitro* with TWS119 were T_{SCM}. We found that TWS119-induced CD44^{low} CD62L^{high} T cells had undergone up to four divisions as manifested by CFSE dilution, and uniformly expressed high levels of the core phenotypic traits of T_{SCM}, namely Sca-1, CD122 and Bcl-2 (Fig. 3a). By contrast, T_N expressed these markers at low levels (Fig. 3a). Similarly, Sca-1, CD122 and Bcl-2 were up-regulated in

CD44^{low}, CD62L^{high} pmel-1 T cells generated *in vitro* in the presence of BIO-acetoxime (Supplementary Fig. 5) or Wnt3A (Supplementary Fig. 6) and *in vivo* after specific-vaccination and TWS119 administration (Supplementary Fig. 7). These activation/memory T cell markers were not exclusively expressed by T$_{SCM}$ but instead only defined T$_{SCM}$ in the context of cells the were also CD44^{low} CD62L^{high} (not shown). Antigen-experienced memory T cells can be distinguished from T$_N$ not only by phenotype but also by a number of functional properties: *i*.) rapid acquisition of effector functions upon antigen re-challenge[26–28]; *ii*.) pronounced cell cycling capacity[29]; *iii*.) robust homeostatic proliferation[30]; and *iv*.) independence of MHC class I for persistence[31] and anti-tumor activity[32]. We found that, unlike T$_N$, TWS119-induced CD44^{low}, CD62L^{high} T cells rapidly released cytokines (IFN-γ and IL-2) upon antigen encounter (Fig. 3b), had undergone more cell division after adoptive transfer into a lymphoreplete host (Fig. 3c) or into sublethally irradiated or genetically lymphodepleted *Tcra*$^{−/−}$ (T cell-deficient) or *Rag1*$^{−/−}$ (T and B cell-deficient) hosts (Fig. 3d), and persisted and mediated tumor destruction ($P < 0.05$) in *B2m*$^{−/−}$ mice (which are MHC class I-deficient) (Fig. 3e,f). Altogether, these findings indicated that Wnt signaling induced the generation of a T$_{SCM}$-like population that possessed the rapid recall ability, proliferative capacity and MHC class I independency that are distinct from naive T cells and characteristic of memory T cells.

The concept of "stemness" encompasses the capability to both self-renew and generate more differentiated, specialized cells. We sought to determine the "stemness" of TWS119-generated CD44^{low}, CD62L^{high} T cells by evaluating their fate after adoptive transfer cells into sublethally irradiated mice. Four weeks later, we found that high percentages of TWS119-generated cells preserved their original CD44^{low}, CD62L^{high} phenotype even after multiple cell divisions, while T$_N$ rapidly acquired CD44 as a function of CFSE dilution ($P < 0.02$) (Fig. 3g,h). The differentiation of TWS119-induced CD44^{low}, CD62L^{high} T cells was not arrested however, because they acquired CD44^{high} expression, albeit at a slower pace. Unlike T$_N$, TWS119-derived CD44^{low}, CD62L^{high}, Sca-1^{high} Tcells robustly proliferated (by 28 days, 95% had undergone cell division) (Fig. 3h), enabling their re-isolation and transfer to a secondary recipient (Supplementary Fig. 8). After four weeks, we found that the secondarily transferred CD44^{low}, CD62L^{high}, Sca-1^{high} Tcells had again regenerated all T cell subsets. Importantly, 43% of the cells retained the T$_{SCM}$ phenotype in spite of a second round of robust proliferation *in vivo* (Supplementary Figure 8). These findings indicated that Wnt signaling promoted the generation of self-renewing, multipotent T$_{SCM}$.

Having established that the CD44^{low}, CD62L^{high} T cells generated in the presence of TWS119 were *bona fide* T$_{SCM}$ and not merely naive, we sought to compare them with the well defined memory T cell subsets, T$_{CM}$ and T$_{EM}$, in secondary challenge experiments. Highly-purified pmel-1 thy1.1$^+$ memory T cell subsets were adoptively transferred into sublethally-irradiated micein combination with recombinant vaccinia-based gp100 vaccine and IL-2. As previously reported by our group and others[33,34], the *in vivo* recall responsesof T$_{CM}$ were greater than T$_{EM}$ (Fig. 4a). T$_{SCM}$, however, robustly expanded by approximately 200-fold in the spleen alone. These levels were ≈ 10-times higher than T$_{CM}$ and ap; 30-times higher than T$_{EM}$ (Fig. 4a). Furthermore, T$_{SCM}$ exhibited an enhanced survival capacity as revealed by the frequencies of pmel-1 cells in the spleens of vaccinated

mice one month after transfer (Fig. 4b). T cell proliferative and survival capacities have been correlated with tumor responses in mice and humans receiving adoptive T cell-based therapies[35,36]. To assess whether the enhanced replicative capability of T_{SCM} would result in superior anti-tumor activity, we adoptively transferred limiting numbers of pmel-1 memory T cell subsets into sublethally-irradiated hosts bearing B16 tumors, in combination with gp100 vaccine and IL-2. As we previously reported[33], T_{CM} conferred superior anti-tumor immunity compared with T_{EM} (tumor regression $P < 0.01$; overall survival $P = 0.0644$) (Fig. 4c). It was striking that minuscule numbers (4×10^4) of T_{SCM} were able to trigger the destruction of bulky tumors (1 cm^3 containing ap; 10^9 cells) and to improve survival (T_{SCM} vs.T_{CM}, $P < 0.005$; T_{SCM} vs. T_{EM} $P < 0.005$) (Fig. 4c). Thus, adoptive transfer of T_{SCM} in combination with tumor-antigen vaccination and exogenous IL-2 produced a far more robust and therapeutically significant secondary response compared with the other memory T cell subsets.

Arrest of lymphocyte differentiation in order to maintain long-lived, self-renewing antigen-experienced T cells with the stem cell-like properties has been postulated as the basis of the continual generation of effector T cells[37], but the transcription factors that regulate this process have not been fully elucidated. Although the physiologic role of Wnt signaling in post-thymic T cell development remains unknown, our data indicate that Wnt can regulate the "stemness" of CD8$^+$ T cells by suppressing their differentiation into T_{EFF}. In addition, other circumstantial evidence supports our findings. We recently reported that high levels of the Wnt transcription factors *Tcf7* and *Lef1* were expressed by T cells whose development into T_{EFF} had been arrested using IL-2[18]. Conversely, *Tcf7*$^{-/-}$ mice reportedly have an increased frequency of T cells displaying a CD44^{high}, CD62L^{low} T_{EFF}/T_{EM} phenotype[6]. Paralleling our own observations in CD8$^+$ T cells, expression of a stabilized form of β-catenin inhibited the proliferation and effector function of CD4$^+$ T cells in a model of inflammatory bowel disease[38]. Furthermore, productive CD4$^+$ T cell memory precursors overexpressed *Ctnnb1* and *Tcf7* as well as *Bcl2* and *Il2rb*[9]. These factors were all implicated in the formation and maintenance of T_{SCM} in the present study.

Our findings also have parallels in stem cell biology where Wnt signaling plays a pivotal role in promoting self-renewal while limiting proliferation and differentiation[2,3]. Using mice overexpressing the Wnt signaling inhibitor Dickkopf1 in the hematopoietic stem cell niche, Fleming *et al.,* have found that hematopoietic stem cells exposed to a Wnt-inhibitory environment were less quiescent and had profound defects in their ability to reconstitute the host after serial transplants[3]. T cell lineage commitment to effector versus memory subsets has been recently linked to the asymmetric segregation and inheritance of proteins that control cell fate specification[39]. Although we do not know the role of Wnt in the asymmetric division of CD8$^+$ T cells, unequal localization and activities of Wnt signaling component including β-catenin have been implicated in cell fate specification in *Caenorhabditis elegans*[40].

The ability to pharmacologically induce T_{SCM} has significant implications for the field of adoptive immunotherapy. The findings that small numbers of T_{SCM} in conjunction with specific vaccination and IL-2 can cause the regression of large established vascularized tumors could reduce the cost and complexity of highly effective therapies based on the

adoptive transfer of anti-tumor T cells[35]. Using existing technology[36], it may be possible to genetically engineer the human counterpart of $CD8^+$ T_{SCM} to express T cell receptors or chimeric antigen receptors while pharamacologically mimicking Wnt signaling. This might ultimately allow for the widespread application of adoptive immunotherapy based on multipotent, highly proliferative, tumor-specific T_{SCM}. Finally, the modulation of Wnt signaling to induce long-term T cell memory might be important for T cell-based vaccines designed to target intracellular pathogens. Increasing data indicate that protection against intracellular pathogens correlates with the induction and maintenance of T_{CM} responses, but these responses have not been reproducibly obtained using current vaccination strategies[24,28,34]. *In vivo* administration of small molecule agonists of Wnt might be useful to consistently achieve this goal.

Methods

Mice and tumor lines

Pmel-1 TCR transgenic (Tg) mice (Jackson Laboratories) and pmel-1 ly5.1 double Tg mice and pmel-1 thy1.1 double Tg mice were previously described[16,17]. B16 (H-2^b), a gp100$^+$ murine melanoma, and the gp100$^-$ MCA-205 (National Cancer Institute Tumor Repository) were maintained in culture media.

Antibodies, flow cytometry and cell sorting

All antibodies were purchased from BD Biosciences. Flow cytometry acquisition was performed on a BD FACSCanto™, or BD FACSCanto™ II Flow cytometer. Samples were analyzed using FlowJo software (Tree Star). Naive and T cell memory subsets were sorted using the BD FACSAria™ cell sorter.

Pharmacologic inhibitors of Gsk-3β and Wnt3A

TWS119, BIO, BIO-acetoxime, Methyl-BIO (EMD biosciences) and Wnt3a (R&D systems) were reconstituted according to the manufacturer's instructions and used in experiments *in vitro* or *in vivo* at indicated doses.

In vitro activation of CD8$^+$ T cells

Pmel-1 splenocytes were stimulated with 1 μM hgp100$_{25-33}$ in a culture media containing 10 ng ml^{-1} of IL-2 (Chiron Corporation). Enriched CD8$^+$ T cells from WT were activated on plate-bound anti-CD3 and 1 μg ml^{-1} soluble anti-CD28 antibody in a culture media containing 10 ng ml^{-1} of IL-2. Enriched CD8$^+$ T cells were depleted of non-CD8$^+$ T cells using a MACS negative selection column (Miltenyi Biotech, Inc).

Cytokine Release and Cytolytic Assays

MCA-205 (2.5×10^4) cells were pulsed with 1 μM hgp100$_{25-33}$ or irrelevant influenza nucleoprotein peptide (np) and incubated overnight with T cells at 1:1 ratio at 37°C. Supernatants were analyzed by murine IFN-γ and murine IL-2 ELISA kits (Pierce-Endogen). For ^{51}Cr release assays, MCA-205 target cells were pulsed with 1 μM hgp100$_{25-33}$ or np and 100 μCi of ^{51}Cr (Amersham Biosciences) for 2 h at 37°C. Labeled

cells (10^3) were incubated with T cells at indicated ratios for 4 h at 37°C. Maximal and spontaneous ^{51}Cr releases were determined by incubating 10^3 labeled targets in either 2% SDS or medium.

Adoptive cell transfer

Adoptive cell transfer, immunization with recombinant poxvirus-based vaccines and tumor experiments were performed as described[16,17,32]. C57BL/6, *Tcra*$^{-/-}$ and *Rag1*$^{-/-}$ (Jackson Laboratories), *B2m*$^{-/-}$ (Taconic) were used as recipients. All animal experiments were conducted with theapproval of the NCI Animal Use and Care Committee.

Enumeration of Adoptively Transferred Cells

At days indicated, mice were sacrificed. Spleens were harvested and homogenized into a single cell suspension using the rubber end of a 3cc syringe and a 40 μM filter cup. Samples were enumerated using trypan blue exclusion and were analyzed by flow cytometry for CD8 and thy.1 expression by cells. The absolute number of pmel-1 cells was calculated by multiplying the splenocyte count by the ratio CD8$^+$ thy1.1$^+$/lymphocyte.

CFSE proliferation assays

CD8$^+$ T cells labeled with 1 μM CFSE (Molecular Probes) were used in adoptive experiments or stimulated *in vitro* as described above.

Real-time reverse transcription-polymerase chain reaction

RNA was isolated using RNeasy mini kit (QIAGEN). cDNA was generated by reverse transcription (Applied Biosystems). Real time-polymerase chain reaction was performed using commercially available probes and primers for the indicated genes (Applied Biosystems) and a Prism 7900HT (Applied Biosystems). The levels of gene expression were calculated relative to the housekeeping genes *β-actin* (*Actb*).

Detection of β-catenin by Western Blot analysis

Cells were lysed in RIPA buffer (Cell Signaling Technology) with protease inhibitor. Protein concentration was quantified with Bio-Rad protein assay. 20 μg of total protein were separated on 4–12% SDS-PAGE gel followed by standard immunoblot with anti-β-catenin (BD Bioscience), anti-Gapdh (Chemicon international) and horseradish peroxidase-conjugated goat anti-mouse antibodies (Santa Cruz Biotechnology).

Electrophoretic mobility shift assay

Nuclear extracts were isolated using the nuclear extract kit (Active Motif) and then incubated (5 μg protein) with poly-dI-dC (1 μg μl^{-1} in TE), 5X Binding Buffer (Promega) and γ^{32}P-ATP labeled oligonucleotide probes (Sense: CACAGAGAAAACAAAGCGCGCTATT; Antisense: AATAGCGCGCTTTGTTTTCTCTGTG), containing the TCF/LEF binding motif AACAAAG. Unlabeled oligonucleotide probes were used as competitors. Samples were incubated 30 min at RT and loaded onto the gel (NuPAGE 4–12% or Bis-Tris Gel Invitrogen). Gel was blotted on a nitrocellulose membrane and exposed to the X-ray film.

Statistical analysis

Tumor slopes were compared using Wilcoxon rank sum test. Survival analyses andgraphs were performed using Kaplan–Meier methods.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Reference List

1. Luckey CJ, et al. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci U S A. 2006; 103:3304–3309. [PubMed: 16492737]

2. Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nature Rev Immunol. 2008

3. Fleming HE, et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell. 2008; 2:274–283. [PubMed: 18371452]

4. Verbeek S, et al. An HMG-box-containing T-cell factor required for thymocyte differentiation. Nature. 1995; 374:70–74. [PubMed: 7870176]

5. Jeannet G, et al. Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood. 2008; 111:142–149. [PubMed: 17906078]

6. Schilham MW, et al. Critical involvement of Tcf-1 in expansion of thymocytes. J Immunol. 1998; 161:3984–3991. [PubMed: 9780167]

7. Willinger T, et al. Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T cell factor-1) following antigen encounter in vitro and in vivo. J Immunol. 2006; 176:1439–1446. [PubMed: 16424171]

8. Hinrichs CS, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 2008; 111:5326–5333. [PubMed: 18276844]

9. Williams MA, Ravkov EV, Bevan MJ. Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory. Immunity. 2008; 28:533–545. [PubMed: 18356084]

10. Ding S, et al. Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci U S A. 2003; 100:7632–7637. [PubMed: 12794184]

11. Roose J, et al. Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science. 1999; 285:1923–1926. [PubMed: 10489374]

12. Hovanes K, et al. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nature Genet. 2001; 28:53–57. [PubMed: 11326276]

13. Mann B, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A. 1999; 96:1603–1608. [PubMed: 9990071]

14. Katoh M, Katoh M. Comparative integromics on FZD7 orthologs: conserved binding sites for PU. 1, SP1, CCAAT-box and TCF/LEF/SOX transcription factors within 5′-promoter region of mammalian FZD7 orthologs. Int J Mol Med. 2007; 19:529–533. [PubMed: 17273804]

15. Zeng YA, Verheyen EM. Nemo is an inducible antagonist of Wingless signaling during Drosophila wing development. Development. 2004; 131:2911–2920. [PubMed: 15169756]

16. Overwijk WW, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003; 198:569–580. [PubMed: 12925674]

17. Gattinoni L, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115:1616–1626. [PubMed: 15931392]

18. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nature Med. 2004; 10:55–63. [PubMed: 14702635]

19. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 2004; 25:471–480. [PubMed: 15559249]

20. Ohteki T, et al. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J Exp Med. 2000; 192:99–104. [PubMed: 10880530]

21. Willert K, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 2003; 423:448–452. [PubMed: 12717451]

22. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nature Rev Immunol. 2006; 6:417–423. [PubMed: 16622477]

23. Pearce EL, et al. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science. 2003; 302:1041–1043. [PubMed: 14605368]

24. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nature Med. 2008; 14:623–628. [PubMed: 18535580]

25. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nature Med. 2005; 11:1299–1305. [PubMed: 16288282]

26. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004; 22:745–763. [PubMed: 15032595]

27. Kaech SM, Wherry EJ. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity. 2007; 27:393–405. [PubMed: 17892848]

28. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006; 211:214–224. [PubMed: 16824130]

29. Tough DF, Sprent J. Turnover of naive- and memory-phenotype T cells. J Exp Med. 1994; 179:1127–1135. [PubMed: 8145034]

30. Surh CD, Sprent J. Homeostatic T cell proliferation: how far can T cells be activated to self-ligands? J Exp Med. 2000; 192:F9–F14. [PubMed: 10952731]

31. Murali-Krishna K, et al. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science. 1999; 286:1377–1381. [PubMed: 10558996]

32. Wrzesinski C, et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest. 2007; 117:492–501. [PubMed: 17273561]

33. Klebanoff CA, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005; 102:9571–9576. [PubMed: 15980149]

34. Wherry EJ, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol. 2003; 4:225–234. [PubMed: 12563257]

35. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006; 6:383–393. [PubMed: 16622476]

36. Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314:126–129. [PubMed: 16946036]

37. Fearon DT, Manders P, Wagner SD. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science. 2001; 293:248–250. [PubMed: 11452114]

38. Ding Y, Shen S, Lino AC, Curotto de Lafaille MA, Lafaille JJ. Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nature Med. 2008; 14:162–169. [PubMed: 18246080]

39. Chang JT, et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science. 2007; 315:1687–1691. [PubMed: 17332376]

40. Mizumoto K, Sawa H. Two betas or not two betas: regulation of asymmetric division by beta-catenin. Trends Cell Biol. 2007; 17:465–473. [PubMed: 17919911]

Figure 1. TWS119 activates Wnt signaling in CD8+ T cells

Naive CD8+ T cells were primed *in vitro* with anti-CD3 (2 µg ml^{-1}) and anti-CD28 (1 µg ml^{-1}) specific antibodies with or without 7 µM TWS119. **a,** Western blot analysis of β-catenin and Gapdh in CD8+ T cells treated with or without TWS119. **b,** Electrophoretic mobility shift assay of nuclear extract from CD8+ T cells treated with or without TWS119 using P32-labeled oligonucleotide probes designed from the TCF/LEF binding region of TCF1 target gene *Fzd* 7. Unlabeled oligonucleotide probes were used as competitor. **c,** Quantitative RT-PCR analysis of the expression of *Tcf7*, *Lef1*, *Jun*, *Fzd7*, and *Nlk* in CD8+ T cells treated with or without TWS119. Data are represented as mean +/− SEM. All data are representative of at least two independently performed experiments.

Figure 2. Wnt signaling inhibits CD8[+] T cell proliferation and effector differentiation
a–c, CFSE-labeled naive pmel-1 CD8[+] T cells were primed *in vitro* with CD8[+] T cell depleted splenocytes pulsed with 1 μM hgp100$_{25-33}$, in conjunction with 10 ng ml[−1] IL-2 and titrated doses of TWS119. Four days following T cell activation, phenotypic (**a**) CFSE dilution assays (**b**) and cytokine and ^{51}Cr release assays (**c**) were performed. Data in panel c are represented as mean +/− SEM. **d,** Quantitative RT-PCR analysis of the expression of *Eomes* in CD8[+] T cells after priming with anti-CD3 and anti-CD28 specific antibodies with or without 7 μM TWS119. Data are represented as mean +/−SEM. **e,** Flow cytometry and enumeration of T cell subsets six days after vaccination with or without TWS119. WT mice

received adoptive transfer of 10^6 naive pmel-1 thy1.1$^+$ CD8$^+$ T cells in conjunction with recombinant fowlpox-based hgp100 vaccine. Mice received four daily doses of TWS119 (at 30 mg kg^{-1}) from day 0 to day 3 or DMSO as control. All data are representative of at least two independently performed experiments.

Figure 3. Wnt signaling promotes the generation of T_{SCM}

CFSE-labeled, naive pmel-1 CD8$^+$ T cells were primed *in vitro* with CD8$^+$ T cell-depleted splenocytes pulsed with 1 μM hgp100$_{25–33}$, in conjunction with 10 ng ml^{-1} IL-2 and 7 μM TWS119. **a,** Flow cytometry analysis of TWS119-treated and naive pmel-1 cells four days following T cell activation. **b,** Cytokine release assay of sorted CD44^{low}CD62L^{high} TWS119-treated and naive pmel-1 cells five days after antigenic stimulation. Data are represented as mean +/− SEM. **c** and **d,** CFSE dilution of sorted CD44^{low}CD62L^{high} TWS119-treated and naive thy 1.1$^+$ (**c**) or ly5.1$^+$ (**d**) pmel-1 cells one month after transfer

into WT (c) and sublethally-irradiated WT, or *Tcra*$^{-/-}$, or *Rag1*$^{-/-}$ mice (d). Data are shown on thy 1.1$^+$ (**c**) or ly5.1$^+$ (**d**) CD8$^+$ lymphocytes. e, Flow cytometry analysis of sorted TWS119-treated and naive ly5.1$^+$ pmel-1 cells one month after transfer into WT or *B2m*$^{-/-}$ mice. Data are shown on ly5.1$^+$, CD8$^+$ lymphocytes. **f,** Tumor treatment of myeloablated WT or *B2m*$^{-/-}$ mice bearing B16 tumors established for 7 days. Mice received age-matched, lineage-depleted bone marrow cells. On the following day, 10^6 CD44^{low}CD62L^{high} TWS119-treated or naive pmel-1 cells were transferred in conjunction with exogenous IL-2.**g** and **h,** Flow cytometry analysis of CFSE-labeled, sorted CD44^{low}CD62L^{high} TWS119-treated and naive ly5.1$^+$ pmel-1 cells one month after transfer into sublethally-irradiated WT mice. Data are represented as the percentage of CD44^{low}CD62L^{high} cells as a function of CFSE dilution of two independent experiments (**g**) and as fraction of cells with any given number of divisions (**h**). All data are representative of at least two independently performed experiments.

a

b

c

Figure 4. T_{SCM} possess enhanced *in vivo* recall response and anti-tumor activity compared to T_{CM} and T_{EM}

Pmel-1 naive CD8$^+$ T cells were primed *in vitro* with splenocytes pulsed with 1 μM hgp100$_{25-33}$, in conjunction with 10 ng ml^{-1} IL-2 with or without 7 μM TWS119. Five days after antigenic stimulation, T_{SCM}, T_{CM} or T_{EM} were sorted based on the phenotype. Sublethally-irradiated WT mice received 5×10^4 pmel-1 T_{SCM}, T_{CM} or T_{EM} in conjunction with a recombinant vaccinia virus encoding hgp100 and exogenous IL-2. **a,** Absolute numbers of adoptively transferred pmel-1 cells (identified by CD8$^+$ thy1.1$^+$ lymphocytes) in the spleens of treated animals. Data are represented as mean +/− SEM. **b,** Flow cytometry

analysis for the expression of CD8 and thy1.1. **c,** Tumor treatment and survival of sublethally-irradiated WT mice bearing B16 tumors established for 10 days ($n = 5$ for all groups) receiving 4×10^4 pmel-1 T_{SCM}, T_{CM} or T_{EM} in conjunction with a recombinant vaccinia virus encoding hgp100 and exogenous IL-2. Data are represented as mean +/− SEM. All data shown are representative of at least two independently performed experiments.